EBV can persist in the body lifelong after an initial infection. It achieves this by establishing a latent infection in B lymphocytes, a type of white blood cell. During latency, EBV expresses certain viral proteins that can interfere with normal cell regulatory processes, potentially leading to uncontrolled cell growth and, ultimately, cancer. This situation is more likely in individuals with weakened immune systems, where the virus can evade immune surveillance.
